XChange TEC.INC RECEIVES NASDAQ MINIMUM BID PRICE DEFICIENCY NOTICE
SHANGHAI, Nov. 13, 2024 /PRNewswire/ -- XChange TEC.INC (NASDAQ: XHG) (the "Company"), today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated November 8, 2024 stating that the Company is not in compliance with the requirement to maintain a minimum bid price of $1 per share as set forth under Nasdaq Listing...
The Shaw Prize Award Presentation Ceremony 2024: 21 Years of Celebrating Excellence in Scientific Achievements
HONG KONG, Nov. 13, 2024 /PRNewswire/ -- The Shaw Prize presented its awards to five Shaw Laureates today at the 2024 Award Presentation Ceremony, held in the Hong Kong Convention and Exhibition Centre. Approximately 600 guests from various sectors participated in the event. (From left to right) Professor Scott D Emr, Professor Stuart Orkin, Dr Swee Lay Thein,...
Zymo Research Fights Back Against Qiagen’s Lawsuit, Asserts Antitrust Violations and Attempts to Stifle Innovation
IRVINE, Calif., Nov. 13, 2024 /PRNewswire/ -- Zymo Research Corporation (Zymo Research), a leader in innovative life science solutions, announced today that it has filed claims in the United District Court for the Central District of California against Qiagen GmbH (Qiagen) alleging that Qiagen has engaged in antitrust violations and improperly...
The Sigourney Award-2024 Recipients Honored For Outstanding Work Advancing Psychoanalytic Principles Globally
Four Recipients' Work From Israel, Sweden, Canada and South Africa Earns The Sigourney Award-2024 SEATTLE, Nov. 12, 2024 /PRNewswire/ -- The Sigourney Award Trust annually recognizes outstanding work that advances psychoanalytic thought and principles throughout the world. Robin A. Deutsch, PhD and Analyst Co-Trustee of The Sigourney Award Trust, today announces three...
Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI
Highlights: ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company,...
Metabolon Services Used in Pioneering Multiomic Research on Brain Metabolism and Neurodegenerative Disorders
Ground-breaking investigation leverages Metabolon's Global Discovery Panel for metabolite genome-wide association study (MGWAS) for cerebrospinal fluid (CSF) and brain metabolite levels as they pertain to neurodegenerative disorders MORRISVILLE, N.C., Nov. 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic,...
Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing
Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug Product, while Waterstone will supply Linker-payload. WUHAN, China, Nov. 12, 2024 /PRNewswire/ --...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe...
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. The safety and tolerability of GZR18 tablets align with the known safety characteristics of GLP-1...
2024 Tsingke High-Impact Literature Compilation – Gene Synthesis
BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published using Tsingke's products and services has grown steadily year after year, continuously driving the advancement of life science research. We have selected two high-impact papers, published in prestigious journals, spanning a range of...
